Since SCCT’s founding in 2001, we’ve had the privilege of working with many of the most respected companies in the pharmaceutical industry.

We believe we have the best network of CNS sites in the Southern California Region. Our three sites in the area—Anaheim, Norwalk and San Bernardino—allow us to leverage high patient enrollment, confidence and retention while maintaining centralized operating procedures and eliminating the need for multiple contracts and regulatory start-up activities. The result: outstanding medical attention for our patients and clean, timely data for our sponsors.

At South Coast Clinical Trials, we understand how much you have invested in your products, and we strive to do our part in bringing safe and effective drugs to market as quickly and safely as possible. We have the unique ability to negotiate a single set of contracts for all three of our sites, as well as obtain IRB approval prior to budgets and contracts being finalized. Such flexibility allows us to realize our goal of reducing  the amount of start-up time necessary to begin site initiation.

Since we first began conducting studies in 2001, we have established a trusted and experienced network of industry professionals to assist with patient recruitment and retention. Because each of our investigators has established private practices within our research sites, we are able to recruit the majority of our trial participants from our investigators’ own patient population. This helps introduce normally research-naive patients into clinical trials that can be both appropriate and beneficial to them.

As a result of this model, SCCT is able to provide the best participant supervision before, during and after a study. In fact, our patient after-care programs are among the best in the industry. Our patients invariably have a high level of comfort because they know that their needs will be addressed. This all translates into quality data for our sponsors.

This approach also allows us to go beyond the industry average for outreach efforts for the minority population. Our investigators’ reputation within their private practices for quality patient care has resulted in a participant base that is 30 percent hispanic and 25 percent Asian and Pacific Islander—traditionally two of the most difficult ethnic groups to reach in medical trials.